{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-043664","form_type":"8-K","ticker":"MOVE","cik":"0001734750","company_name":"Corvex, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.808952+00:00","generated_at":"2026-06-01T23:23:23.302940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Movano Health reports Q1 revenue $852k, operating loss $5.8M; closes $24M private placement","bullets":["Q1 2024 revenue $852,000 from 5,305 Evie Rings shipped; operating loss $5.8M vs $7.2M a year ago.","Closed $24.1M private placement on April 4, 2024, including investment from a tier-1 medical device company.","FDA 510(k) decision for Evie Med Ring pulse oximeter expected July 2024; SpO2 trial RMSE 2.46% (below 3.5% FDA guidance).","Planning arterial blood pressure study in June using arterial line for continuous data.","Cash and cash equivalents $2.1M at March 31, 2024; D2C orders paused pending improvements."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-043664","json":"https://secwatch.observer/filing/0001213900-24-043664.json","markdown":"https://secwatch.observer/filing/0001213900-24-043664.md","text":"https://secwatch.observer/filing/0001213900-24-043664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1734750/000121390024043664/0001213900-24-043664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1734750/000121390024043664/ea0206242-8k_movano.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:23:23.302940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c15221a0be6a5738afce597f9dbed171e0624e6","claim":"Corvex, Inc. reported the quarter ended March 31, 2024 results: revenue $852,000.","evidence_excerpt":"board of directors. Movano Health intends to use the net proceeds from the financing for working capital and general corporate purposes. ● In Q1 2024, Movano Health generated $852,000 in revenue. The Company shipped 5,305 Evie Rings in the period. ● The Company reported an operating loss of $5.8 million in Q1 2024, compared to an operating loss of $7.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1734750/000121390024043664/0001213900-24-043664-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$852,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}